CBU
BBIO icon

CIBC Bancorp USA’s BridgeBio Pharma BBIO Stock Holding History

CIBC Bancorp USA’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949K Buy
13,947
+1,446
+12% +$101K ﹤0.01% 1116
2026
Q1 		$928K Buy
+12,501
New +$906K ﹤0.01% 1061
2025
Q3 		$866K Buy
+16,669
New +$813K ﹤0.01% 708

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

CIBC Bancorp USA's BBIO Position: Q2 2026 in Review

CIBC Bancorp USA increased its BridgeBio Pharma (BBIO) stake by 12% in Q2 2026, buying an estimated $101K and bringing the position to 13,947 shares worth $949K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

CIBC Bancorp USA first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • CIBC Bancorp USA held 13,947 shares of BridgeBio Pharma worth $949K as of Q2 2026.
  • CIBC Bancorp USA bought 1,446 BridgeBio Pharma shares in Q2 2026, an estimated $101K.
  • BridgeBio Pharma made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1116 holding.
  • CIBC Bancorp USA first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.